Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Terns Pharmaceuticals, Inc. (TERN)

9.21   0.27 (3.02%) 02-02 15:08
Open: 8.75 Pre. Close: 8.94
High: 9.4 Low: 8.75
Volume: 93,508 Market Cap: 456(M)

Technical analysis

as of: 2023-02-02 2:45:48 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 12.46     One year: 14.55
Support: Support1: 8.66    Support2: 7.42
Resistance: Resistance1: 10.67    Resistance2: 12.46
Pivot: 8.57
Moving Average: MA(5): 8.65     MA(20): 8.62
MA(100): 6.94     MA(250): 4.38
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 81.3     %D(3): 59.2
RSI: RSI(14): 59
52-week: High: 10.67  Low: 1.45
Average Vol(K): 3-Month: 321 (K)  10-Days: 142 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ TERN ] has closed below upper band by 9.9%. Bollinger Bands are 41.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.23 - 9.29 9.29 - 9.34
Low: 8.61 - 8.67 8.67 - 8.72
Close: 8.86 - 8.95 8.95 - 9.03

Company Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Headline News

Wed, 01 Feb 2023
Good Tern Co-op hosts Valentine chocolate cake baking class -

Tue, 31 Jan 2023
Barclays PLC Grows Stake in Terns Pharmaceuticals, Inc. (NASDAQ ... - MarketBeat

Sun, 29 Jan 2023
A tern for the best - Geelong Independent

Fri, 27 Jan 2023
Birders head out on sponsored walk to 'tern the tide' on bird flu ... - Surfbirds News

Fri, 27 Jan 2023
Conservation measures for Terns within Lady's Island Lake Special ... -

Thu, 26 Jan 2023
Electric cargo bikes: load-carrying ebikes explained - BikeRadar

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 25 (M)
% Held by Insiders 9.46e+006 (%)
% Held by Institutions 4.4 (%)
Shares Short 326 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -5.316e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -5
Return on Assets (ttm) 365.5
Return on Equity (ttm) -20.2
Qtrly Rev. Growth 1e+006
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.76
Qtrly Earnings Growth -2.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -43 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 434600
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.